Skip to main content
The Wider Implications of Dactylitis

Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA),

Dr. John Cush RheumNow

1 month 4 weeks ago
The Wider Implications of Dactylitis Dactylitis, AKA the "sausage digit", is a hallmark of psoriatic arthritis (PsA), but as Possemato and colleagues point out, it is fundamentally a clinical sign, and not a diagnosis. https://t.co/HRaIvMHMSV https://t.co/XOcHbFVMsS
During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention.  We are all familiar with the famous 1905 quote, “Those who cannot remember the past are condemned to repeat it." (from philosopher George Santayana)
When Gout Flares, So Does the Cardiovascular System

We have spent decades teaching that a gout flare is a joint problem

Dr. John Cush RheumNow

1 month 4 weeks ago
When Gout Flares, So Does the Cardiovascular System We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title https://t.co/HCUQVaor4f
Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Dr. John Cush RheumNow

1 month 4 weeks ago
Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ https://t.co/zN41GC5T15
Upgrading & Maximizing the Classics

Panelists: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikul

Dr. John Cush RheumNow

1 month 4 weeks ago
Upgrading & Maximizing the Classics Panelists: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikuls Dr. Jack Cush (moderator) https://t.co/gO4CQD2f19 https://t.co/ESSLL0iK8F
2 T2T RCTs of 383 gout pts starting allopurinol - 31% had tophi. At 12 mos achieving target uric acid (<0.36mmol/L) w

Dr. John Cush RheumNow

1 month 4 weeks ago
2 T2T RCTs of 383 gout pts starting allopurinol - 31% had tophi. At 12 mos achieving target uric acid (<0.36mmol/L) was same in pts with and without tophi (70.3 vs 73.6), as was the %gout flares in month 11 (71.4% vs 79.7%; p=0.21). Allopurinol T2T success not influenced by https://t.co/zr7K8Y2Bqz
Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a definition of remission in gout.
QD Clinic: RA Mimics Gout
Swimming Reduces Disability from Low Back Pain

Swimming is commonly recommended for patients with chronic low back pai

Dr. John Cush RheumNow

1 month 4 weeks ago
Swimming Reduces Disability from Low Back Pain Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically https://t.co/OfxsvRjyJg
Evidence-Based Dietary Recommendations for Gout

Gout, historically referred to as the “disease of kings,” was once

Dr. John Cush RheumNow

1 month 4 weeks ago
Evidence-Based Dietary Recommendations for Gout Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is the most common inflammatory arthritis https://t.co/uIrSeOjxJZ
New Avacopan Analysis Sent to FDA
  • MedPage Today
After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January.Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA in a bid to keep the embattled drug for severe anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis on the market.
DERM on RheumNow (July 2026)
3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STO

Dr. John Cush RheumNow

1 month 4 weeks ago
3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z
×